Publication: The clobazam metabolite N-desmethyl clobazam is an α2 preferring benzodiazepine with an improved therapeutic window for antihyperalgesia
The clobazam metabolite N-desmethyl clobazam is an α2 preferring benzodiazepine with an improved therapeutic window for antihyperalgesia
Date
Date
Date
Citations
Ralvenius, W. T., Acuña, M. A., Benke, D., Matthey, A., Daali, Y., Rudolph, U., Desmeules, J., Zeilhofer, H. U., & Besson, M. (2016). The clobazam metabolite N-desmethyl clobazam is an α2 preferring benzodiazepine with an improved therapeutic window for antihyperalgesia. Neuropharmacology, 109, 366–375. https://doi.org/10.1016/j.neuropharm.2016.07.004
Abstract
Abstract
Abstract
Data from genetically modified mice suggest that benzodiazepine (BDZ)-site agonists with improved selectivity for α2-subtype GABAA receptors (α2GABAAR) are potentially useful for the treatment of neuropathic pain. Subtype-selective compounds available for preclinical tests in rodents support this concept but have not been approved for human use, hindering proof-of-concept studies in patients. We recently proposed that N-desmethyl clobazam (NDMC), the main metabolite of the licensed BDZ clobazam (CBZ), is responsible for most of the an
Additional indexing
Creators (Authors)
Volume
Volume
Volume
Page range/Item number
Page range/Item number
Page range/Item number
Page end
Page end
Page end
Item Type
Item Type
Item Type
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Keywords
Language
Language
Language
Publication date
Publication date
Publication date
Date available
Date available
Date available
ISSN or e-ISSN
ISSN or e-ISSN
ISSN or e-ISSN
OA Status
OA Status
OA Status
Free Access at
Free Access at
Free Access at
Publisher DOI
Citations
Ralvenius, W. T., Acuña, M. A., Benke, D., Matthey, A., Daali, Y., Rudolph, U., Desmeules, J., Zeilhofer, H. U., & Besson, M. (2016). The clobazam metabolite N-desmethyl clobazam is an α2 preferring benzodiazepine with an improved therapeutic window for antihyperalgesia. Neuropharmacology, 109, 366–375. https://doi.org/10.1016/j.neuropharm.2016.07.004